Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-2017 (Cenobamate) in Japanese PGTC Seizure Patients
NCT06579573Phase 3Recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- Jul 2022
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of cenobamate, sponsored by Ono Pharmaceutical. Primary endpoint: Percentage Change in generalized tonic-clonic (PGTC) seizure frequency. Started Jul 2022; status: recruiting.
02
Drugs
cenobamate
Beyond the preview
Go deeper on NCT06579573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06579573.